Predictive Factors to Effectively Terminate Paroxysmal Atrial Fibrillation by Blocking Atrial Selective Ionic Currents

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

June 30, 2023

Study Completion Date

August 31, 2023

Conditions
Paroxysmal Atrial Fibrillation
Interventions
DRUG

Vernakalant

Initial infusion: 3 mg/kg intravenously over a 10 minute period. For patients weighing ≥ 113 kg, the maximum initial dose will be 339 mg. If conversion to sinus rhythm does not occur within 15 minutes after the end of the initial infusion, a second 10 minute infusion of 2 mg/kg will be administered. For patients weighing ≥ 113 kg, the maximum second infusion will be 226 mg.

DRUG

Flecainide

2 mg /kg (max 150 mg) intravenously over 10 minutes.

Trial Locations (1)

28040

Hospital Clínico Universitario San Carlos, Madrid

All Listed Sponsors
collaborator

Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

OTHER

lead

David Filgueiras-Rama

OTHER

NCT03005366 - Predictive Factors to Effectively Terminate Paroxysmal Atrial Fibrillation by Blocking Atrial Selective Ionic Currents | Biotech Hunter | Biotech Hunter